The current reality is that no effective entity exists to pull together the spectrum of scientific, medical, regulatory, and business interests to bring promising therapeutic agents for children more swiftly to the point of evaluation in clinical trials. Over the past couple of years, the Children's Cause for Cancer Advocacy has been working closely with the Institute of Medicine, the National Cancer Institute, pharmaceutical companies, and leading pediatric oncologists to find a way to dramatically shorten the time needed to develop agents targeted at childhood cancer.